Trade Equillium, Inc. - EQ CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
| Spread | 0.0338 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
Equillium Inc ESG Risk Ratings
‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.
| Prev. Close* | 1.7881 |
| Open* | 1.7581 |
| 1-Year Change* | 141% |
| Day's Range* | 1.6781 - 1.7681 |
| 52 wk Range | 0.45-1.35 |
| Average Volume (10 days) | 117.55K |
| Average Volume (3 months) | 3.03M |
| Market Cap | 27.74M |
| P/E Ratio | -100.00K |
| Shares Outstanding | 35.12M |
| Revenue | 42.63M |
| EPS | -0.24 |
| Dividend (Yield %) | N/A |
| Beta | 1.11 |
| Next Earnings Date | Mar 21, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 17, 2024 | 1.7881 | -0.0400 | -2.19% | 1.8281 | 1.8481 | 1.6481 |
| Apr 16, 2024 | 1.8181 | 0.0900 | 5.21% | 1.7281 | 1.8281 | 1.6981 |
| Apr 15, 2024 | 1.7581 | -0.0900 | -4.87% | 1.8481 | 1.8581 | 1.6981 |
| Apr 12, 2024 | 1.8481 | -0.0600 | -3.14% | 1.9081 | 1.9281 | 1.8381 |
| Apr 11, 2024 | 1.9281 | 0.0200 | 1.05% | 1.9081 | 1.9481 | 1.8981 |
| Apr 10, 2024 | 1.8481 | -0.0400 | -2.12% | 1.8881 | 1.9481 | 1.8081 |
| Apr 9, 2024 | 1.9381 | 0.0500 | 2.65% | 1.8881 | 2.0481 | 1.8881 |
| Apr 8, 2024 | 1.9181 | -0.1800 | -8.58% | 2.0981 | 2.1581 | 1.8981 |
| Apr 5, 2024 | 2.1281 | -0.0100 | -0.47% | 2.1381 | 2.2581 | 2.0981 |
| Apr 4, 2024 | 2.1881 | -0.1500 | -6.42% | 2.3381 | 2.3881 | 2.1881 |
| Apr 3, 2024 | 2.3181 | 0.1700 | 7.91% | 2.1481 | 2.3681 | 2.1281 |
| Apr 2, 2024 | 2.1781 | 0.0800 | 3.81% | 2.0981 | 2.2881 | 2.0581 |
| Apr 1, 2024 | 2.0981 | -0.2000 | -8.70% | 2.2981 | 2.2981 | 2.0081 |
| Mar 28, 2024 | 2.2681 | 0.2300 | 11.29% | 2.0381 | 2.4181 | 2.0381 |
| Mar 27, 2024 | 2.0381 | 0.1200 | 6.26% | 1.9181 | 2.0881 | 1.9181 |
| Mar 26, 2024 | 1.9781 | -0.2900 | -12.79% | 2.2681 | 2.2981 | 1.6581 |
| Mar 25, 2024 | 2.3981 | -0.3500 | -12.74% | 2.7481 | 2.8781 | 2.3081 |
| Mar 22, 2024 | 2.7481 | 0.0300 | 1.10% | 2.7181 | 2.9781 | 2.7181 |
| Mar 21, 2024 | 2.7581 | 0.0000 | 0.00% | 2.7581 | 2.8481 | 2.7181 |
| Mar 20, 2024 | 2.8481 | 0.2200 | 8.37% | 2.6281 | 2.8781 | 2.5781 |
Equillium, Inc. Events
| Time (UTC) | Country | Event |
|---|---|---|
| Thursday, May 9, 2024 | ||
| Time (UTC) 10:59 | Country US
| Event Q1 2024 Equillium Inc Earnings Release Q1 2024 Equillium Inc Earnings ReleaseForecast -Previous - |
| Tuesday, May 21, 2024 | ||
| Time (UTC) 16:00 | Country US
| Event Equillium Inc Annual Shareholders Meeting Equillium Inc Annual Shareholders MeetingForecast -Previous - |
| Wednesday, May 22, 2024 | ||
| Time (UTC) 20:00 | Country US
| Event Equillium Inc Annual Shareholders Meeting Equillium Inc Annual Shareholders MeetingForecast -Previous - |
| Wednesday, August 7, 2024 | ||
| Time (UTC) 10:59 | Country US
| Event Q2 2024 Equillium Inc Earnings Release Q2 2024 Equillium Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total revenue | 15.759 | 0 | 0 | 0 | 0 |
| Total Operating Expense | 77.835 | 37.786 | 29.548 | 26.727 | 8.61559 |
| Selling/General/Admin. Expenses, Total | 17.239 | 11.407 | 10.164 | 9.087 | 3.67244 |
| Research & Development | 60.196 | 26.379 | 20.584 | 17.64 | 4.94315 |
| Operating Income | -62.076 | -37.786 | -29.548 | -26.727 | -8.61559 |
| Interest Income (Expense), Net Non-Operating | -0.633 | -1.016 | -0.623 | 1.112 | -4.63489 |
| Net Income Before Taxes | -62.428 | -39.052 | -29.813 | -25.6 | -13.2505 |
| Net Income After Taxes | -62.428 | -39.052 | -29.813 | -25.6 | -13.2505 |
| Net Income Before Extra. Items | -62.428 | -39.052 | -29.813 | -25.6 | -13.2505 |
| Total Extraordinary Items | |||||
| Net Income | -62.428 | -39.052 | -29.813 | -25.6 | -13.2505 |
| Income Available to Common Excl. Extra. Items | -62.428 | -39.052 | -29.813 | -25.6 | -13.2505 |
| Income Available to Common Incl. Extra. Items | -62.428 | -39.052 | -29.813 | -25.6 | -13.2505 |
| Diluted Net Income | -62.428 | -39.052 | -29.813 | -25.6 | -13.2505 |
| Diluted Weighted Average Shares | 33.728 | 28.8063 | 20.3555 | 17.3781 | 12.1903 |
| Diluted EPS Excluding Extraordinary Items | -1.85093 | -1.35568 | -1.46461 | -1.47312 | -1.08697 |
| Dividends per Share - Common Stock Primary Issue | 0 | ||||
| Diluted Normalized EPS | -1.83907 | -1.35568 | -1.52357 | -1.47312 | -1.08697 |
| Other, Net | 0.281 | -0.25 | 0.358 | 0.015 | |
| Unusual Expense (Income) | 0.4 | -1.2 | |||
| Revenue | 15.759 |
| Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
|---|---|---|---|---|---|
| Total revenue | 9.124 | 8.879 | 15.759 | 0 | 0 |
| Total Operating Expense | 12.715 | 12.987 | 13.717 | 13.237 | 13.552 |
| Selling/General/Admin. Expenses, Total | 3.105 | 3.715 | 5.192 | 4.466 | 4.064 |
| Research & Development | 9.61 | 9.272 | 8.525 | 8.771 | 9.488 |
| Unusual Expense (Income) | 0 | 0 | |||
| Operating Income | -3.591 | -4.108 | 2.042 | -13.237 | -13.552 |
| Interest Income (Expense), Net Non-Operating | 0.368 | 0.407 | -0.07 | -0.137 | -0.195 |
| Other, Net | -0.112 | -0.179 | 0.801 | -0.281 | -0.382 |
| Net Income Before Taxes | -3.335 | -3.88 | 2.773 | -13.655 | -14.129 |
| Net Income After Taxes | -3.343 | -3.94 | 2.773 | -13.655 | -14.129 |
| Net Income Before Extra. Items | -3.343 | -3.94 | 2.773 | -13.655 | -14.129 |
| Net Income | -3.343 | -3.94 | 2.773 | -13.655 | -14.129 |
| Income Available to Common Excl. Extra. Items | -3.343 | -3.94 | 2.773 | -13.655 | -14.129 |
| Income Available to Common Incl. Extra. Items | -3.343 | -3.94 | 2.773 | -13.655 | -14.129 |
| Diluted Net Income | -3.343 | -3.94 | 2.773 | -13.655 | -14.129 |
| Diluted Weighted Average Shares | 34.4498 | 34.4142 | 34.374 | 34.3521 | 34.2926 |
| Diluted EPS Excluding Extraordinary Items | -0.09704 | -0.11449 | 0.08067 | -0.3975 | -0.41201 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | -0.09704 | -0.11449 | 0.08067 | -0.3975 | -0.41201 |
| Revenue | 9.124 | 8.879 | 15.759 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total Current Assets | 76.735 | 83.37 | 85.174 | 55.431 | 67.0991 |
| Cash and Short Term Investments | 71.023 | 80.711 | 82.163 | 53.143 | 65.9133 |
| Cash & Equivalents | 59.107 | 50.366 | 23.982 | 13.219 | 28.5085 |
| Prepaid Expenses | 2.874 | 2.659 | 3.011 | 2.288 | 1.18584 |
| Total Assets | 78.421 | 85.405 | 85.428 | 55.539 | 67.1626 |
| Property/Plant/Equipment, Total - Net | 1.582 | 1.882 | 0.239 | 0.093 | 0.06352 |
| Total Current Liabilities | 32.038 | 8.915 | 7.245 | 3.883 | 2.02798 |
| Accounts Payable | 3.977 | 1.225 | 2.766 | 1.873 | 1.11915 |
| Accrued Expenses | 7.647 | 6.262 | 2.813 | 2.01 | 0.90883 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 46.479 | 18.9 | 15.574 | 13.691 | 2.22751 |
| Total Long Term Debt | 3.239 | 8.75 | 8.275 | 9.681 | 0 |
| Long Term Debt | 3.239 | 8.75 | 8.275 | 9.681 | 0 |
| Other Liabilities, Total | 11.202 | 1.235 | 0.054 | 0.127 | 0.19953 |
| Total Equity | 31.942 | 66.505 | 69.854 | 41.848 | 64.9351 |
| Common Stock | 0.003 | 0.002 | 0.002 | 0.001 | 0.00079 |
| Additional Paid-In Capital | 204.268 | 176.618 | 141.074 | 82.938 | 80.4414 |
| Retained Earnings (Accumulated Deficit) | -172.405 | -109.977 | -70.925 | -41.112 | -15.5124 |
| Total Liabilities & Shareholders’ Equity | 78.421 | 85.405 | 85.428 | 55.539 | 67.1626 |
| Total Common Shares Outstanding | 34.4142 | 29.4557 | 24.7531 | 17.4256 | 17.3762 |
| Short Term Investments | 11.916 | 30.345 | 58.181 | 39.924 | 37.4048 |
| Property/Plant/Equipment, Total - Gross | 1.831 | 2.029 | 0.313 | 0.122 | 0.06974 |
| Accumulated Depreciation, Total | -0.249 | -0.147 | -0.074 | -0.029 | -0.00622 |
| Other Equity, Total | 0.076 | -0.138 | -0.297 | 0.021 | 0.00528 |
| Other Long Term Assets, Total | 0.104 | 0.153 | 0.015 | 0.015 | |
| Current Port. of LT Debt/Capital Leases | 5.714 | 1.428 | 1.666 | ||
| Total Receivables, Net | 2.838 | ||||
| Accounts Receivable - Trade, Net | 2.838 | ||||
| Other Current Liabilities, Total | 14.7 |
| Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 53.911 | 57.356 | 70.22 | 76.735 | 46.776 |
| Cash and Short Term Investments | 46.306 | 48.378 | 61.992 | 71.023 | 44.522 |
| Cash & Equivalents | 34.382 | 25.624 | 24.503 | 59.107 | 25.729 |
| Short Term Investments | 11.924 | 22.754 | 37.489 | 11.916 | 18.793 |
| Prepaid Expenses | 3.836 | 5.235 | 4.804 | 2.874 | 2.254 |
| Total Assets | 55.225 | 58.764 | 71.79 | 78.421 | 48.631 |
| Property/Plant/Equipment, Total - Net | 1.235 | 1.321 | 1.474 | 1.582 | 1.742 |
| Other Long Term Assets, Total | 0.079 | 0.087 | 0.096 | 0.104 | 0.113 |
| Total Current Liabilities | 28.199 | 25.218 | 32.02 | 32.038 | 14.93 |
| Accounts Payable | 3.635 | 3.026 | 5.692 | 3.977 | 2.469 |
| Accrued Expenses | 8.168 | 7.953 | 5.847 | 7.647 | 6.747 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 0 | 0 | 5.714 | 5.714 | 5.714 |
| Total Liabilities | 31.117 | 31.783 | 42.521 | 46.479 | 20.471 |
| Total Long Term Debt | 0 | 0 | 1.841 | 3.239 | 4.616 |
| Long Term Debt | 0 | 0 | 1.841 | 3.239 | 4.616 |
| Other Liabilities, Total | 2.918 | 6.565 | 8.66 | 11.202 | 0.925 |
| Total Equity | 24.108 | 26.981 | 29.269 | 31.942 | 28.16 |
| Common Stock | 0.003 | 0.003 | 0.003 | 0.003 | 0.003 |
| Additional Paid-In Capital | 207.045 | 206.326 | 205.306 | 204.268 | 203.142 |
| Retained Earnings (Accumulated Deficit) | -183.398 | -179.688 | -176.345 | -172.405 | -175.178 |
| Other Equity, Total | 0.458 | 0.34 | 0.305 | 0.076 | 0.193 |
| Total Liabilities & Shareholders’ Equity | 55.225 | 58.764 | 71.79 | 78.421 | 48.631 |
| Total Common Shares Outstanding | 35.1193 | 34.5685 | 34.4142 | 34.4142 | 34.3521 |
| Property/Plant/Equipment, Total - Gross | |||||
| Accumulated Depreciation, Total | |||||
| Total Receivables, Net | 3.769 | 3.743 | 3.424 | 2.838 | |
| Accounts Receivable - Trade, Net | 3.769 | 3.743 | 3.424 | 2.838 | |
| Other Current Liabilities, Total | 16.396 | 14.239 | 14.767 | 14.7 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -62.428 | -39.052 | -29.813 | -25.6 | -13.2505 |
| Cash From Operating Activities | -8.733 | -32.081 | -24.624 | -22.949 | -7.52625 |
| Cash From Operating Activities | 0.118 | 0.072 | 0.045 | 0.023 | 0.0061 |
| Non-Cash Items | 53.558 | 5.201 | 3.889 | 1.917 | 5.41712 |
| Changes in Working Capital | 0.019 | 1.698 | 1.255 | 0.711 | 0.30101 |
| Cash From Investing Activities | 18.684 | 27.406 | -18.592 | -2.166 | -37.4343 |
| Capital Expenditures | -0.279 | -0.057 | -0.202 | -0.074 | -0.03486 |
| Cash From Financing Activities | -1.215 | 31.061 | 53.945 | 9.836 | 66.3656 |
| Issuance (Retirement) of Stock, Net | 0.214 | 31.061 | 53.945 | -0.045 | 64.7665 |
| Issuance (Retirement) of Debt, Net | -1.429 | 0 | 9.881 | 1.59901 | |
| Net Change in Cash | 8.741 | 26.384 | 10.763 | -15.289 | 21.405 |
| Other Investing Cash Flow Items, Total | 18.963 | 27.463 | -18.39 | -2.092 | -37.3995 |
| Foreign Exchange Effects | 0.005 | -0.002 | 0.034 | -0.01 | |
| Cash Interest Paid | 0.847 | 0.836 | 0.839 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -3.94 | -62.428 | -65.201 | -51.546 | -37.417 |
| Cash From Operating Activities | -7.995 | -8.733 | -36.458 | -23.393 | -12.134 |
| Cash From Operating Activities | 0.031 | 0.118 | 0.086 | 0.056 | 0.025 |
| Non-Cash Items | -1.439 | 53.558 | 27.612 | 26.067 | 24.302 |
| Changes in Working Capital | -2.647 | 0.019 | 1.045 | 2.03 | 0.956 |
| Cash From Investing Activities | -25.181 | 18.684 | 11.706 | -3.294 | -11.985 |
| Capital Expenditures | 0 | -0.279 | -0.277 | -0.277 | -0.223 |
| Other Investing Cash Flow Items, Total | -25.181 | 18.963 | 11.983 | -3.017 | -11.762 |
| Cash From Financing Activities | -1.429 | -1.215 | 0.141 | 0.141 | 0 |
| Issuance (Retirement) of Stock, Net | 0.214 | 0.141 | 0.141 | 0 | |
| Foreign Exchange Effects | 0.001 | 0.005 | -0.026 | -0.012 | -0.003 |
| Net Change in Cash | -34.604 | 8.741 | -24.637 | -26.558 | -24.122 |
| Issuance (Retirement) of Debt, Net | -1.429 | -1.429 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Equillium, Inc. Company profile
About Equillium Inc
Equillium, Inc. is a clinical-stage biotechnology company. The Company develops products to treat severe autoimmune and inflammatory disorders with unmet medical needs. The Company's initial product candidate, itolizumab (EQ001), is a clinical-stage, monoclonal antibody that selectively targets CD6, a co-stimulatory receptor differentially expressed on subsets of pro-inflammatory T cells. The Company's CD6 plays a central role in the modulation of effector T cell, or Teff cell, activity and trafficking. Activated Teff cells drive several immuno-inflammatory diseases across therapeutic areas including transplant science, systemic autoimmunity, pulmonary, neurologic, gastrointestinal, renal, vascular, ophthalmic and dermatologic disorders. It also provides structured-domain peptides, including BNZ-1 and BNZ-2, entirely in-house from product discovery platform. These lead product candidates are multi-specific inhibitors that targets range of immuno-inflammatory indication.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Equillium Inc revenues was not reported. Net loss increased 31% to $39.1M. Higher net loss reflects Research and development - Balancing val increase of 30% to $24.4M (expense), General and administrative - Balancing increase of 11% to $9M (expense), Other expense, net decrease from $358K (income) to $250K (expense).
| Industry: | Pharmaceuticals (NEC) |
2223 Avenida de La Playa Ste 105
LA JOLLA
CALIFORNIA 92037-3217
US
Income Statement
- Annual
- Quarterly
News
Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024
US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024
Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024
US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024
How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024
A way forward: a roundup of recent central bank decisions
Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.
12:47, 22 March 2024
Bank of Japan Preview: will the BOJ end negative interest rates?
The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.
08:44, 18 March 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com